Nav: Home

Children's Hospital Los Angeles initiates clinical trial for treatment-resistant leukemia

March 29, 2016

The Children's Center for Cancer and Blood Diseases (CCCBD) at Children's Hospital Los Angeles is one of the first sites in the world to offer a promising new investigational therapy to treat pediatric acute lymphoblastic leukemia (ALL).

The most common cancer diagnosed in children, ALL accounts for 25% of pediatric malignancy. Although the cure rate is high for pediatric ALL, the disease remains a leading cause of cancer related mortality in children.

This new trial was initiated in conjunction with Santa Monica-based biopharmaceutical company Kite Pharma, Inc. The study, referred to as ZUMA 4 (NCT02625480), tests a novel therapy called KTE-C19, which uses a patient's own T cells to target the antigen CD19, a protein expressed on the cell surface in most cases of childhood ALL.

Alan S. Wayne, MD, director of the CCCBD, is the lead principal investigator for this clinical trial that is now open to patients with ALL whose disease is resistant to, or has relapsed following, standard chemotherapy or stem cell transplant.

"This approach has ushered in a whole new era of cancer immunotherapy," says Wayne, who is also associate director for Pediatric Oncology at the USC Norris Comprehensive Cancer Center and Professor of Pediatrics at the Keck School of Medicine, University of Southern California.

In this trial, T cells - a primary type of immune cell - are genetically engineered to recognize the CD19 protein on the surface of leukemia cells. In this approach, the patient's own T cells are collected and modified in the laboratory to express what is called a chimeric antigen receptor (CAR). The T cells expressing the CAR are then returned to the patient where they can attack and eliminate leukemia cells.

Wayne previously led the development of the predecesor trial that treated 21 children at the Pediatric Oncology Branch of the National Cancer Institute at the National Institutes of Health. The results of that study, first published online in the medical journal Lancet in 2014, showed unprecedented complete response rates of 70 percent in children with relapsed or chemotherapy refractory ALL. An accompanying editorial stated: "This approach is without question the most significant therapeutic advance in ALL for a generation, and might represent the beginning of a new era of engineered T cells for cancer therapy".

The CCCBD is the largest pediatric hematology, oncology and blood and marrow transplant program in the western United States. In 2015, The U.S. News & World Report ranked the CCCBD as the top pediatric hematology/oncology program in California and #8 in the nation.

This new study is part of the CCCBD's growing Cellular Therapeutics Program designed to propel the next generation of innovation in childhood cancer.
-end-
More information about the ZUMA-4 clinical study (NCT02625480) is available on http://www.clinicaltrials.gov.

Children's Hospital Los Angeles

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...